BRWM
MACK

B. Riley Wealth Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

B. Riley Wealth Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-64
Closed -$6K – 942
2015
Q2 		$6K Buy
+64
New +$6.09K ﹤0.01% 845
2015
Q1 		– Sell
-330
Closed -$29K – 1134
2014
Q4 		$29K Sell
330
-4
-1% -$291 0.02% 500
2014
Q3 		$23K Buy
334
+38
+13% +$2.03K 0.02% 573
2014
Q2 		$16K Buy
+296
New +$15K 0.01% 723

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
LIM
Lagoda Investment Management New York $162M AUM 49.7% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

B. Riley Wealth Management's MACK Position: Q3 2015 in Review

B. Riley Wealth Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2015, closing a stake of 64 shares — an estimated $6K sold.

B. Riley Wealth Management first reported a position in MACK in Q2 2014 and held it in 4 quarters. The position peaked at $29K in Q4 2014. 135 funds tracked by Wall St. Rank hold MACK as of Q3 2015.

  • B. Riley Wealth Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • B. Riley Wealth Management sold 64 Merrimack Pharmaceuticals, Inc. shares in Q3 2015, an estimated $6K.
  • B. Riley Wealth Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2014 and held it in 4 quarters.
  • B. Riley Wealth Management's Merrimack Pharmaceuticals, Inc. position peaked at $29K in Q4 2014.
  • 135 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2015.

Based on B. Riley Wealth Management's 13F filing for Q3 2015, filed 13 Oct 2015.